PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), announced today certain financial and operational results for the three months ended September 30, 2022, and provided other business updates.
- Research and development (R&D) expenses declined approximately 60% to $0.6 million in the third quarter of 2022, compared to approximately $1.6 million in the third quarter of 2021.
- The Companys 2022 third quarter conference call with analysts and investors will be held today at 8:30am ET.
- To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com and follow us on LinkedIn and Twitter .
- These forward-looking statements represent PLxs estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.